Post-hoc analyses extend understanding of the efficacy and safety of lurasidone

Takeda Pharmaceuticals International GmbH and Sunovion Pharmaceuticals Inc. announced the results from three post-hoc analyses evaluating the efficacy and safety of Latuda® (lurasidone) in patients with schizophrenia at the 23rd European Congress of Psychiatry (EPA). The analyses suggest that lurasidone is associated with reduced hostility in patients with schizophrenia and reduced frequency of certain adverse events commonly associated with antipsychotic treatment.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Tags: *** Editor's Pick Clinical trials European Conferences and Symposia Practical therapeutics Industry News Neurology Psychiatry Patient care Research antipyschotic treatment. PANSS EPA Latest News lurasidone prolactin levels schi Source Type: news